乳腺癌P-gp、GST-π和TopoⅡ的表达及其意义  

Expressions of P-gp,GST-π and Topo Ⅱ in breast carcinoma and their significance

作　　者：李占文[1] 杨华锋[1] 李振平[1] 刘纯[1] 范风风[1] 胡云锵[1] 

机构地区：[1]宁波市妇女儿童医院,浙江宁波315012

出　　处：《现代实用医学》2006年第5期303-305,共3页Modern Practical Medicine

摘　　要：目的探讨P-糖蛋白(P-gp),谷胱甘肽S转移酶π(GST-π),DNA拓扑异构酶Ⅱ(TopoⅡ)在乳腺癌组织中的表达及其意义。方法采用免疫组化SP法对78例术前未行化疗患者的乳腺癌组织切片中P-gp、GST-π、TopoⅡ的表达进行分析。结果P-gp、GST-π、TopoⅡ的阳性表达率分别为38.5%、46.2%、73.1%,与年龄、肿瘤大小、ER/PR和HER2状况无关。腋淋巴结阳性组P-gp和GST-π的阳性表达率与阴性组比较,差异有统计学意义(2χ=5.175,2χ=4.614,P<0.05);肿瘤不同分期的P-gp的阳性表达率差异有统计学意义(2χ=5.848,P<0.05)而且随分期增高而增高。结论乳腺癌组织的原发多药耐药与P-gp、GST-π、TopoⅡ的表达有关,化疗前对它们进行检测可为化疗药物的选择及预后判断提供参考依据。Objective To study the expressions of P-glycoprotein （ P-gp ）, glutathione-S-transferases π（GST-π） and topoisomerase Ⅱ （Topo Ⅱ ） in breast carcinoma tissues and their significance. Methods Seventy-eight breast carcinoma tissues obtained from the patients without chemotherapy before operation were detected for the expressions of P-gp, GST-π and Topo Ⅱ by immunohistochemical method. Results In breast carcinoma tissues,the positive expression rate of P-gp, GST-π and Topo Ⅱ was 38.5% ,46.2% and 73.1%, respectively. The difference of the expressions of 3 genes in the patients＇ age, size of tumor, expression of ER/PR and HER2 was not significant （P 〉 0.05 ）. There was significant relationship among the P-gp, GST-π positivity and lymph node metastasis（x^ 2 = 5. 175 ,x^2 = 4. 614,P 〈0.05） as well as between the P-gp and TNM stage（x^2 = 5. 848,P 〈 0.05）. Conclusion The expressions of P-gp, GST-π and Topo Ⅱ are related to the primary multidrug resistance in breast carcinoma tissues. Detecting the expressions of the three genes before chemotherapy will provide evidence for the selection of drugs and for the judgement of the prognosis.

关 键 词：乳房肿瘤 抗药性 多药 P糖蛋白 谷胱甘肽转移酶 DNA拓扑异构酶类 Ⅱ型 

分 类 号：R737.9[医药卫生—肿瘤]